

1 **Natural products targeting macrophages in tumor**  
2 **microenvironment are a source of potential antitumor agents**

3 Qiu-Ping Liu<sup>a</sup>, Yu-Ying Chen<sup>a</sup>, Pei An<sup>a</sup>, Khalid Rahman<sup>b</sup>, Xin Luan<sup>a\*</sup>, Hong Zhang<sup>a\*</sup>

4

5 <sup>a</sup> Shanghai Frontiers Science Center of TCM Chemical Biology; Institute of  
6 Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional  
7 Chinese Medicine, Shanghai 201203, China

8 <sup>b</sup> School of Pharmacy and Biomolecular Sciences, Faculty of Science, Liverpool John  
9 Moores University, Liverpool, United Kingdom

10

11 **\*Correspondence:**

12 Hong Zhang

13 Email address: [zhanghong@shutcm.edu.cn](mailto:zhanghong@shutcm.edu.cn)

14 Phone & Fax: 021-51322720

15 Address: No. 1200, Cailun Road, Pudong New Area, Shanghai, 201203, China

16 Xin Luan

17 Email address: [luanxin@shutcm.edu.cn](mailto:luanxin@shutcm.edu.cn)

18 Phone & Fax: 021-51322428

19 Address: No. 1200, Cailun Road, Pudong New Area, Shanghai, 201203, China

20

## ABSTRACT

*Background:* Macrophages are one of the major cell types in the immune system and are closely related to tumor development, which can be polarized into M1 type with anti-tumor activity or M2 type with pro-tumor activity. The infiltration of more macrophages into tumor predicts poorer prognosis due to their more exhibition of M2 phenotype under the influence of many factors in the tumor microenvironment (TME). Therefore, reverse of M2 macrophage polarization in TME is conducive to the suppression of tumor deterioration and understanding the influencing factors of macrophage polarization is helpful to provide new ideas for the subsequent targeting macrophages for tumor therapy.

*Purpose:* This review summarizes the effects of TME on macrophage polarization and natural products against M2 macrophage polarization, which may provide some directions for tumor therapy.

*Methods:* The search of relevant literature was conducted using the PubMed, Science Direct, CNKI and Web of Science databases with the search terms “macrophage”, “tumor microenvironment”, “natural product” and “tumor”.

*Results:* The mutual transformation of M1 and M2 phenotypes in macrophages is influenced by many factors. Tumor cells affect the polarization of macrophages by regulating the expression of genes and proteins and the secretion of cytokines. The expression of some genes or proteins in macrophages is also related to their own polarization. Many natural products can reverse M2 polarization of macrophages which

has been summarized in this review.

**Conclusion:** Regulation of macrophage polarization in TME can inhibit tumor development, and natural products have the potential to impede tumor development by regulating macrophage polarization.

**Key words:** Natural product; Macrophage; Polarization; Tumor microenvironment; Immune

**Abbreviations:** AIE, Aggregation-induced emission; ALOX5AP, Arachidonate 5-Lipoxygenase activating protein; ARCR, *Astragalus mongholicus* Bunge-Curcuma aromatica *Salisb.* extract; ASO, Antisense oligo nucleotide; CAFs, Cancer-associated fibroblasts; CTHRC1, Collagen triple helix repeat containing 1; C5aR, Complement 5a receptor; DCLK1, Doublecortin-like kinase 1; DC-SIGN, DC-specific ICAM-3-grabbing non-integrin; DHA, Dihydroartemisinin; DLBCL, Diffuse large B-cell lymphoma; EAT, Ethyl acetate fraction of *Adenophoratriphyllavar.japonica*; ESCC, Esophageal squamous cell carcinoma; FGL2, Fibrinogen-like protein 2; FoxQ1, Forkhead box Q1; GBC, Gallbladder cancer; GBM, Glioblastoma multiforme; GLSP, *G. lucidum* spore polysaccharide; Gpr132, G protein-coupled receptor 132; HNSCC, Head and neck squamous cell carcinoma; HMGA2, High-mobility gene group A2; HPV, Human papilloma virus; ICAM-1, Intercellular cell adhesion molecule-1; IL-10, Interleukin-10; IFN- $\gamma$ , Interferon gamma; IL1RL10, Interleukin-1 receptor like 1; ISG15, Interferon-stimulated gene 15; NF- $\kappa$ B, Nuclear factor kappa-B; NPC, Nasopharyngeal carcinoma; NSCLC, Non-small cell lung cancer; MEMA, Methylene chloride extract of *Morus alba* L; MK2, MAPK-activated protein kinase 2; MIF,

Migration inhibitory factor; MMP, Matrix metalloproteinases; MMR, Macrophage  
 mannose receptor; M-CSF, macrophage colony-stimulating factor; ObR, leptin receptor;  
 PAI-1, Plasminogen activator inhibitor-1; PINK1, PTEN-induced kinase 1; PTX,  
 Paclitaxel; PDA, Pancreatic ductal adenocarcinoma; PGE2, Prostaglandin E2; PTEN,  
 Phosphatase and tensin homolog deleted on chromosome 10; PPARc, Peroxisome  
 proliferator-activated receptor-c; Prxs, Peroxiredoxins; RKIP, Raf kinase inhibitory  
 protein; ROS, Reactive oxygen species; SI-CLP, Stabilin-1 interacting chitinase-like  
 protein; SLC2A, Solute carrier 2A; SMS2, Sphingomyelin synthase 2; SPON2,  
 Spondin-2; SUCNR1, Succinic acid receptor; STAT, Signal transducer and activator of  
 transcription; SYK, Spleen tyrosine kinase; S100A9, S100 calcium-binding protein A9;  
 TAMs, Tumor-associated macrophages; TDO2, Tryptophan 2,3-dioxygenase 2; TFEB,  
 Transcription factor EB; TGF- $\beta$ , Transforming growth factor- $\beta$ ; TME, Tumor  
 microenvironment; TLR7, Toll-like receptor 7; TNBC, Triple-negative breast cancer;  
 TNFSF15, Tumor necrosis factor superfamily-15; VEGF, Vascular endothelial growth  
 factor; YPF, Yu-Ping-Feng

## Introduction

Tumor microenvironment (TME) plays an important role in tumor metastasis, immunosuppression and chemotherapy resistance, which mainly includes tumor cells, infiltrating immune cells (macrophages, lymphocytes, dendritic cells, etc.) and infiltrating stromal cells (cancer-associated fibroblasts, endothelial cells, etc.) (Kenny et al., 2007; Mao et al., 2021). Macrophages as the most widely infiltrating immune cells in TME provide support for the development of tumors (Qian and Pollard, 2010). Tumor-associated macrophages (TAMs) recruit endothelial cells by secreting a variety of cytokines such as vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMP), thereby inducing angiogenesis in tumor sites which is the main reason for tumor growth and invasion (Cendrowicz et al., 2021). TAMs also inhibit the cytotoxic activity of T lymphocytes and NK cells by releasing immunoregulatory factors such as prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), interleukin-10 (IL-10) and transforming growth factor- $\beta$  (TGF- $\beta$ ) to exert immunosuppressive effect (Li et al., 2011), indicating that TAMs are a potential target for tumor therapy. Plasticity is one of the key features of macrophages, which can make their phenotypes and functions adapt to the needs of the surrounding environment to promote tumor deterioration.

As shown in Figure 1, macrophages can be divided into classically activated macrophages (M1 type) and alternatively activated macrophages (M2 type) (Liu and Wang, 2020). Interferon gamma (IFN- $\gamma$ ) induces the polarization of macrophages into M1, promoting T helper (Th) 1 immune response and anti-tumor activity (Locati et al.,

2013), while IL-4/IL-13 elicits their polarization into M2, increasing anti-inflammatory Th2 immune response and pro-tumor activity. In addition, M2 macrophages can be further subdivided into M2a, M2b, M2c and M2d under different stimuli. M2a and M2b play an immune regulatory role and drive Th2 response, while M2c plays a leading role in inhibiting immune response and promoting tissue remodeling. M2d, also known as tumor associated macrophages (TAMs), is closely associated with tumor progression(Li et al., 2011).

Macrophages are one of the main immune cells in the immune system, which can regulate homeostasis, resist pathogens and promote wound healing(Wang et al., 2021a). In TME, most macrophages show M2 phenotype with tumor promoting effects due to the influence of the surrounding environment. Nevertheless, a small number of macrophages still display M1 phenotype with anti-tumor ability. Therefore, understanding the regulatory factors related to the differentiation and function of macrophages is conducive to the development of drugs targeting macrophages further. This review summarizes the regulatory mechanism of macrophage polarization in TME and natural products against M2 polarization, so as to provide directions for tumor therapy.

## **Tumor microenvironment facilitates polarization and recruitment of macrophages**

### *Regulation of macrophage polarization and recruitment*

Macrophages exhibit different phenotypes due to the influence of surrounding environment, which is related to the expression of proteins or genes in macrophages. Therefore, the effects of genes or proteins in macrophages on their functions are summarized below to provide some idea for regulating macrophages in TME. It is well known that TAMs exhibit various functions in TME, such as promoting angiogenesis, mediating immune escape and accelerating tumor cell migration. In addition, TAMs still maintain phagocytic function and present anti-tumor activity under appropriate re-education which is regulated by protein or gene in macrophages (Lecoultre et al., 2020). VentX, a master regulator of macrophage plasticity is associated with the phagocytic activity of macrophages, which is significantly decreased in TAMs in the pancreatic ductal adenocarcinoma (PDA) microenvironment. The recovery of VentX expression in TAMs promotes phagocytosis, but the mechanism remains unclear (Le et al., 2020). The metabolism is also related to macrophage phenotypes and functions (Zhang et al., 2021a). As mentioned above, macrophages can exhibit M1 and M2 phenotypes, which have different metabolic patterns due to their different functions. M1 macrophages are characterized by aerobic glycolysis, while M2 by oxidative phosphorylation. IL-33/ST2 axis was reported to be associated with oxidative phosphorylation and glycolysis in macrophages, which enhances mitophagy through the activation of mTOR and then

increase the expression of genes related to M2 polarization, promoting M2 polarization further (Xu et al., 2021b). Integrin is a cell adhesion and signal protein which plays an important role in the biological function of cells (Slack et al., 2022). The overexpression of integrin  $\beta 3$  on the surface of TAMs *in vivo* and *in vitro* accelerates M2 polarization through activating peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) (Shu et al., 2020). Collagen triple helix repeat containing 1 (CTHRC1), a secreted ECM protein, promotes the recruitment of TAMs through integrin  $\beta 3$ /PI3K/Akt/CX3CR1 signaling pathway (Li et al., 2019) and promotes M2 polarization through the activation of pSTAT6 (Bai et al., 2020). SPON2 in macrophages activates RhoA and Rac1 by acting on  $\alpha 4 \beta 1$  integrin, promotes F-actin reorganization and further increases M1-like macrophage recruitment (Zhang et al., 2018b). However, SPON2 has been reported to be associated with a poor prognosis in colorectal cancer and promote macrophage M2 polarization through activating integrin  $\beta 1$ /PYK2 axis (Huang et al., 2021a). ROS is involved in a plethora of processes in cells and plays an important role in macrophage-mediated immunity (Herb and Schramm, 2021). Isoprenaline facilitates the M2 polarization of breast cancer macrophages through inhibiting autophagy probably by regulation of ROS/ERK and mTOR signaling pathways, indicating that repression of autophagy may be a possible treatment for cancer (Shan et al., 2017). M2 macrophages modulated the secretion of IL-1 $\beta$  by regulating fatty acid oxidation in ROS and NLRP3 dependent manner, thus promoting the development of cancer (Zhang et al., 2018a). Peroxiredoxins (Prxs) are a family of antioxidant enzymes that possess the ability of removing H<sub>2</sub>O<sub>2</sub> and peroxynitrite. When the lung carcinoma cells with or without



knockdown of Prx5 are injected to WT or Prx5<sup>-/-</sup> mice, the volume of the tumor is related to the expression of Prx5 in the mice and but not in the cancer cells injected, indicating that tumor growth is uncorrelated with the expression of Prx5 in tumor cells. The deficiency of Prx5 in macrophages induces ROS accumulation, promoting their own M2-like phenotype (Seong et al., 2021).

Cytokines promote tumor development and interleukin-10 (IL-10) is known as an anti-inflammatory and immunomodulatory cytokine which has been proved to suppress inflammatory response through inhibiting the activation of macrophages (Kim et al., 2020). The expression and secretion of IL-10 in TAMs are closely related to their functions. OVOL2 expression is higher in M1 macrophages than in M2. The overexpression of OVOL2 decreases M2 polarization of macrophages by inhibiting the transcription of IL-10 (Wu et al., 2022). The overexpression of nuclear factor of activated T cells 1 (NFATc1) in macrophages is associated with tumor growth. The tumor volume in mice subcutaneously inoculated with sh-NFATc1 TAM + SiHa is lower than that with shNC TAM + SiHa, revealing the important role of NFATc1 in the tumor growth. Mechanically, the overexpression of NFATc1 in macrophages facilitates M2 polarization by regulating c-myc/PKM2 pathway to enhance IL-10 secretion (Tan et al., 2022). Chemokines are chemotactic cytokines which can cause the targeted migration of leukocytes. Most cells in TME secrete a series of chemokines that affect TME by recruiting stromal cells and stimulating angiogenesis (Balkwill, 2004). According to the number and spacing of the first two cysteine residues in the amino-terminal part of the protein, chemokines are divided into four groups, i.e. C, CC, CXC

and CX3C(Slettenaar and Wilson, 2006). Macrophages in TME can recruit more from other sites and induce their polarization by secreting chemokines. PTEN (phosphatase and tensin homolog deleted on chromosome 10) is regarded as a new tumor suppressor regulated by NHERF-1, whose deficiency drives M2-like polarization of macrophages in TME by increasing CCL2 and VEGF-A (Li et al., 2015). CCL2 and IL-6 recruit monocytes to TME and increases their polarization into M2 macrophages by inhibiting caspase-8 cleavage and enhancing autophagy in macrophages(Roca et al., 2009). S100 calcium-binding protein A9 (S100A9) is an inflammatory microenvironment-related secretory protein up-regulated in TAMs and acts on tumor cells through AGER/NF- $\kappa$ B axis, thereby facilitating the transcription of CCL2, which accelerates the expression of S100A9 in macrophages in return(Wei et al., 2021). The deficiency of MAPK-activated protein kinase 2 (MK2) in macrophages inhibits tumor angiogenesis by regulating the secretion of CXCL-12/SDF-1, suggesting that MK2 inhibitor may be a potential treatment for cancer(Suarez-Lopez et al., 2020). Chemokine receptors also play an important role in the polarization of macrophages. The up-regulation of CX3CR1 in TAMs is related to the poor prognosis of cancer. The knockout of CX3CR1inhibits tumor angiogenesis and liver metastasis in mice and the mechanism needs further investigation (Zheng et al., 2013).

The aberrant expression of proteins or genes in macrophages can induce macrophage polarization to promote their recruitment from other sites. Therefore, understanding the proteins or genes related to the polarization and function of macrophages is instrumental in provide an idea for the subsequent therapy targeting

macrophages. The regulation of polarization and recruitment of macrophages is shown in Table 1.

### *Effects of tumor cells on polarization of macrophages*

Macrophages can exhibit specific phenotypes when affected by the surrounding environment. The communication between tumor cells and macrophages in TME plays a key role in mediating the function of macrophages. Signals from tumor cells can induce the additional functions of macrophages(Jiang et al., 2021; Pan et al., 2020). Ovarian cancer stem cells promote macrophage M2 polarization by activating the PPAR $\gamma$  and inhibiting NF- $\kappa$ B pathway(Deng et al., 2015). The M2 polarization and PD-L1 expression of macrophages are also facilitated by hemangiosarcoma cells(Gulay et al., 2022). Exosomes from metastatic osteosarcoma cells regulated TAMs signaling to enhance M2 phenotype, thereby eliciting an immunosuppression of tumor-promoting microenvironment by producing TGFB2(Wolf-Dennen et al., 2020). As shown in Figure 2, the communication between different types of cells can be mediated by exosomes. The aberrant expression of some RNAs in tumor cells affects macrophage function by packaging these RNAs in exosomes. miRNAs in exosomes derived from bladder cancer cells induce macrophage polarization into immunosuppressive phenotype by activating the PTEN/AKT/STAT3/6 pathway(Jiang et al., 2021). miR-21-5p is up-regulated in exosomes of esophageal cancer cells, which converts M0 macrophages into M2 through activation of the PTEN/AKT/STAT6 pathway(Song et al., 2021a). cir\_0001142 is highly expressed in breast cancer and

endoplasmic reticulum stress promotes the release of exosomes encapsulating circ\_0001142 in breast cancer cells, which interferes with the process of autophagy and polarization of macrophages(Lu et al., 2022). Overexpression of Linc00514 in breast cancer cells enhances the phosphorylation of STAT3 and then activates Jagged1-mediated Notch signaling pathway to accelerates the polarization of co-cultured macrophages into M2(Tao et al., 2020). In addition, mutations of genes in tumor cells can result in the changes in macrophage function. The mutation of CREBBP/EP300 in B-lymphoma patient-derived tumor xenografted mice increases M2 polarization of TAMs through FBXW7-NOTCH-CCL2/CSF1 axis(Huang et al., 2021c). KRAS is the most frequently mutated oncogene in human neoplasia. Oxidative stress induced KRAS mutation in pancreatic cancer cells and mutated KRAS packaged into exosomes are then taken up by macrophages through an AGER-dependent mechanism, which causes macrophages switch to an M2-like pro-tumor phenotype via STAT3-dependent fatty acid oxidation(Dai et al., 2020). Macrophages cultured in p53 mutant tumor cell medium reduces M1 markers and inhibit phagocytosis, indicating that p53 mutation facilitates M2 polarization of macrophages(Xu et al., 2022).

As displayed in Figure 3, some metabolites such as succinic acid and lactic acid in TME are closely related to the deterioration of tumors(Zhao et al., 2017). The level of succinate and succinic acid receptor (SUCNR1) in the serum of patients with lung cancer is higher than that of healthy people. Mechanically, succinic acid released by cancer cells activates the succinic acid receptor (SUCNR1) signal on macrophages,

which is polarized into TAMs through the PI3K- HIF-1 $\alpha$  axis, thus promoting the development of tumors(Wu et al., 2020). Lactic acid, a key metabolite of tumors in TME, is 40 times higher in tumor cells than in normal cells, which is closely associated with the deterioration of tumors. Lactic acid drives tumor progression by inhibiting anti-tumor immunity, increasing tumor angiogenesis and regulating tumor microenvironment(Feng et al., 2017; Végran et al., 2011). Lactic acid in TME is also closely relevant to the function of macrophages. Gastric cancer cell produced lactic acid accelerates M2 polarization of macrophages(Zhang and Li, 2020). Breast cancer derived lactate acid increases macrophage M2 polarization by activating the ERK/STAT3 signaling pathway(Mu et al., 2018) while lactic acid from cancer cells induces M2 polarization by activating Gpr132 in macrophages(Chen et al., 2017). M2 polarization of macrophages is facilitated by transitional bladder carcinoma cells secreted lactic acid(Zhao et al., 2015). The abnormal expression of some proteins in tumor cells is also associated with lactate secretion. SLC2A3 overexpression in gastric cancer cells promotes the release of lactic acid, thereby increasing the polarization and infiltration of M2 macrophages(Yao et al., 2020). The expression of some proteins or genes in tumor cells can induce the recruitment and polarization of macrophages by regulating the secretion of chemokines, further promoting the deterioration of tumors (Figure 4). FoxQ1, also known as HFH1, is a member of the forkhead transcription factor family, which is related to the poor prognosis of many tumors. The expression of FoxQ1 in hepatocellular carcinoma cells accelerates the recruitment of macrophage infiltration through CCL2 secretion, which in turn drives hepatocellular carcinoma

metastasis(Xia et al., 2014). The number of TAMs and the volume of tumor decrease in PYK2 knockout mice. Mechanically, PYK2 interferes with the polarization of M2 macrophages by reducing the expression of N11ICD, which drives the secretion of CCL2 in breast cancer cells to increase the angiogenesis and tumor-promoting phenotypes in macrophage through IL4R $\alpha$ /pSTAT6 axis. (Muller et al., 2022). The expression of SI-CLP (Stabilin-1 interacting chitinase-like protein) in mouse TS/A cells impedes tumor growth through suppressing the recruitment of macrophages by inhibition of the secretion of CCL2 in breast cancer cells(Yin et al., 2020). The high-mobility gene group A2 (HMGA2), an oncoprotein, is aberrantly overexpressed in colorectal cancer cells. It is bound directly to STAT3 promoter to activate the transcription, which induces the secretion of CCL2, thereby promoting macrophage recruitment(Wang et al., 2022). Overexpression of Spi-B is associated with poor prognosis of patients with lung cancer, which facilitates TAM recruitment by up-regulating CCL4 expression(Huang et al., 2021b). The expression of Twist1 in tumor cells drives macrophage recruitment and tumor angiogenesis by secreting CCL2(Low-Marchelli et al., 2013). The expression of RKIP is correlated with the expression of CCL5 in breast cancer and the overexpression of RKIP in breast cancer cells inhibits macrophage infiltration to tumor sites through the decrease of CCL5 expression(Datar et al., 2015). The overexpression of BRD4 is associated with poor prognosis in gastrointestinal stromal tumor which enhances the expression of CCL2 in cancer cells by activation of the NF- $\kappa$ B signaling pathway, thereby promoting macrophage recruitment to tumor sites(Mu et al., 2019). Table 2 exhibits the effects of exosomes

from tumor cells on macrophage polarization and recruitment.

### *Effects of other cells on polarization of macrophages*

The communication between macrophages and other cells in TME also modulates the function of macrophages. In pancreatic ductal adenocarcinoma (PDAC), CAFs induce monocytes to transform into tumor-promoting TAM phenotype by secreting macrophage colony-stimulating factor (M-CSF) and enhancing ROS production in monocytes (Zhang et al., 2017). Mesenchymal stromal cells injected into paracarcinoma could secrete IFN- $\gamma$ , leading to the polarization of macrophages into M1 phenotype (Relation et al., 2018). Interestingly, salt extracellular environment induces an anti-inflammatory M2 macrophage phenotype (Amara et al., 2016) and higher matrix stiffness strengthens the polarization of M2 macrophages through the integrin  $\beta$ 5-FAK-MEK1/2-ERK1/2 pathway (Xing et al., 2021). In addition, supplements of some nutrients can prevent macrophage M2 polarization. Dietary protein or amino acid inhibit M2 polarization of macrophages through ROS/mTOR, thus restoring tumor immune response (Orillion et al., 2018). Ocoxin® oral solution (OOS) is a nutritional supplement, which can impede the M2 protumoral polarization of macrophages (Hernandez-SanMiguel et al., 2019).

### **Bacteria regulate polarization of macrophages**

The function of macrophages is not only affected by various cells in TME, but is also related to microorganisms. Bacterial infection plays a dual role in the development

of cancer. On the one hand, it activates the immune system, which not only has antibacterial effect but also possesses antitumor activity, and the competition of essential nutrients between bacteria and tumor cells in TME also exert anti-tumor effects(Azevedo et al., 2020; Yasunaga and Matsuoka, 2018). On the other hand, bacterial infection can also promote the occurrence of cancer. Globally, 15% of cancers are caused by carcinogenic pathogens, such as HPV infection for cervical cancer, *Helicobacter pylori* for gastric cancer, *Candida albicans* for oral squamous cell carcinoma and *Streptococcus hemoglobin* for bladder cancer(Sawant et al., 2020), indicating that the occurrence of tumors can be induced by bacterial infection. Besides, bacterial infection can also affect macrophage polarization. *Fusobacterium nucleatum* enhances the infiltration and M2 polarization of macrophages by activating CCL20 to promote tumor growth(Xu et al., 2021a). *Listeria infection* drives TAM to exhibit the function of M1 macrophages, with the ability of phagocytic function and tumoricidal activation to exert antitumor effect(Rai et al., 2012). *Akkermansia muciniphila* impede the development of colon cancer by inducing TLR2/NLRP3-mediated M1-like TAM activation(Fan et al., 2021). In addition, some microbial metabolites are also associated with the polarization of macrophages. Pullulan is a non-ionic, non-immunogenic and edible polysaccharide produced by *Aureobasidium pullulan*. Spermine modified pullulan (PS) activates Akt-, Erk-, and JNK-mediated signaling pathways and NF- $\kappa$ B signaling pathway by up-regulation of TLR1, TLR3, and TLR4, resulting in the polarization of M2 macrophages into M1 phenotype, which alleviates the immunosuppressive TME and restores the function of T cells(Xie et al., 2019).



## Natural products targeting macrophages in TME

Macrophages are crucial to tumor development and at present, some compounds with the ability of regulating macrophage polarization and recruitment to tumor sites have been found(Saeedifar et al., 2021). Many extracts of traditional Chinese medicine have been reported to have anti-tumor effects, some of which can regulate the polarization of macrophages. KSG-002, an extract of radices *Astragalus membranaceus* and *Angelica gigas* with the ratio of 3:1, inhibits macrophage infiltration through increase of NF- $\kappa$ B-mediated TNF $\alpha$  production with no toxicity to rat intestinal epithelial (RIE) cells(Woo et al., 2013). *Astragalus mongholicus* Bunge-*Curcuma aromatica* Salisb. (ARCR) is a typical mixture of medication which can treat a variety of malignancies through impeding M2 polarization of macrophages by regulating the Sp1/ZFAS1/miR-153-3p/CCR5 axis, thereby preventing the development of colon cancer. ARCR at the dose of 6 g/kg/d<sup>-1</sup> has no obvious toxicity and adverse reactions in orthotopic transplantation colon cancer model mice (Gu et al., 2022; Liu et al., 2022a). The extract of *Cordyceps sinensis* accelerates M1 polarization of macrophages by activating the NF- $\kappa$ B signaling pathway(Li et al., 2020). *Cordyceps sinensis* has been considered to be a medicinal plant and health food. However, its long-term intake may lead to health risks due to the content of As and the related products(Liu et al., 2022b). Some polysaccharides extracted from natural products can also regulate the phenotype of macrophages. Oligo-Fucoidan, a sulfated polysaccharide isolated from the brown seaweed, induces monocyte differentiation into M1-like macrophages

and repolarization of M2 macrophages into M1 phenotype(Chen et al., 2020a). G. lucidum spore polysaccharide (GLSP) increases M1 polarization of macrophages but does not repress the activity on macrophage growth (Song et al., 2021b). Homogeneous polyporus polysaccharide facilitates M1 polarization of macrophages of bladder cancer. But its toxicity is still unclear(Jia et al., 2021).

Chinese medicine formula is characterized by multiple components and multiple targets, some of which have been reported to regulate the polarization of macrophages. Aiduqing formula increases M1 polarization by inhibiting CXCL1 secretion in macrophages without noticeable hepatotoxicity, nephrotoxicity, or hematotoxicity observed *in vivo* (Li et al., 2021). Yu-Ping-Feng (YPF), an ancient Chinese herbal decoction, induces M1 polarization of macrophages by promoting phosphorylation of STAT1 but does not affect the osmotic pressure of the medium and the activity of LLC cells and macrophages within 24 h up to the dose of 1 mg/mL (Wang et al., 2019).

In addition, some natural compounds isolated from Chinese medicines can also affect the development of tumors by regulating macrophages. Astragaloside IV is a natural compound from Chinese herb *Radix Astragali* and fulfills pleiotropic function in several cancers. It hinders the development of ovarian cancer by inhibiting HMGB1/TLR4 pathway in macrophages with little cytotoxicity within experimental doses (Wang et al., 2021b) and also promotes M1 polarization of macrophages in colorectal cancer without toxicity observed in the test concentration (Liu et al., 2020). Resveratrol isolated from *Polygonum cuspidatum* increases M1 polarization of macrophages and the ratio of M1/M2(Cheuk et al., 2022). But the low bioavailability

is its main limitation, which is extensively metabolized in the liver and intestines (Robertson et al., 2022). In addition, resveratrol analogue HS-1793 induces TAMs differentiation into anti-tumor phenotype by enhancement of IFN- $\gamma$  production (Jeong et al., 2014). Dihydroartemisinin (DHA), the active metabolite of artemisinin, is one of the most important and effective antimalarial drugs, which is able to regulate various aspects of immune response (Xiao et al., 2022). Dihydroartemisinin increases M1 polarization of macrophages in TME of Lewis lung carcinoma via AKT/mTOR pathway without obvious cytotoxicity observed in mice and cells at the experimental doses (Xiao et al., 2022) and suppresses M2 polarization by inhibiting STAT3 activation in head and neck squamous cell carcinoma (HNSCC) (Chen et al., 2020b). Natural products associated with macrophage polarization and recruitment are shown in Table 3.

## Discussion

At present, the treatments of tumors mainly include surgical resection, chemotherapy and radiotherapy, all of which have side effects related to macrophages. Surgical resection removes in situ tumors, but tumor metastasis is the major reason for cancer deterioration. Circulating tumor cells play a key role in tumor metastasis which can combine with TAMs in peripheral blood to promote tumor metastasis (Adams et al., 2014; Salmaninejad et al., 2019). As a major cancer treatment, chemotherapy causes many side effects and drug resistance, which is also associated with macrophages. For example, sorafenib, a well-known targeted anti-tumor drug, can promote TAMs

infiltration in tumor tissue and further leads to immunosuppressive microenvironment in patients with hepatocellular carcinoma(Zhang et al., 2021b). Radiotherapy can directly elicit the death of tumor cells, but also damages immunogenic cells to promote tumor immunity. Moreover, macrophages are also the most radiation-resistant cells, which can produce a large number of antioxidant molecules, thus limiting the effect of radiotherapy(Prenen and Mazzone, 2019). Therefore, targeting macrophages can alleviate some limitations of current tumor treatment, which is expected to become an adjuvant therapy in the future.

Immunotherapy has become a hot topic in cancer treatment recently and activation of immune system can combat cancer cells(Johdi and Sukor, 2020). Restoration of the normal immune function in TME can enhance the clearance of cancer cells without damaging normal cells. Macrophages, as one of the main cells in the immune system, possess the function of clearing antigen. However, macrophages in TME mainly play a role in promoting tumor development due to the influence of the surrounding environment. Furthermore, the overexpression of CD47 on the surface of many cancer cells transmit the “don’t eat me” signal by interaction with SIRP $\alpha$  protein on macrophages, which inhibits the phagocytosis of macrophages(Chen et al., 2019; Qiu et al., 2018). Therefore, suppressing CD47 expression on tumor cells can promote macrophage phagocytosis and hinder tumor deteriorate. There are a large number of macrophages in tumor microenvironment. Once these are transformed into anti-tumor cells, the expression of “don’t eat me” signal on tumor cell surface will be inhibited, thus preventing the development of tumors. As displayed in Figure 5, the polarization

of macrophages can be regulated by knockout or overexpression of some genes or proteins in TME, which could provide an idea for tumor treatment by targeting macrophages. But the adverse effect remains unclear, which needs to be investigated further.

As mentioned above, some natural products inhibit macrophage polarization and recruitment. However, due to unclear target and off-target toxicity, it is particularly important to design some drug delivery systems improving the targetability and toxicity of compounds. Nanotechnology provides great opportunities for targeted regulation of macrophages polarization, which could improve cancer immunotherapy(Ding et al., 2021). Immunostimulation usually starts from the interaction between nanocarriers and innate immune cells such as macrophages(Andon et al., 2017). Therefore, one of the most critical issues for nanomedicine to strengthen immunotherapy is the intrinsic effect of drug-free liposomes on activation and polarization of macrophages through cell interaction. The synthesized drug-free mannosylated liposomes enhance anti-tumor immunity by inhibiting macrophage polarization from M2 to M1(Ye et al., 2019). Therefore, the preparation of some natural products with definite efficacy into nanomedicine is helpful to improve efficacy and reduce toxicity. Macrophage mannose receptor (MMR or CD206) expressed in TAMs is a key promoter of tumor progression and a major opponent for cancer therapy (De Vlaeminck et al., 2019). Therefore, it is possible to improve the targeting of drugs by designing a vector targeting MMR. Besides, exosomes also play an important role in TME. Can a drug-coating exosome be designed to target macrophages? Bacterial infection can activate the immune system.

Maybe a vaccine can be designed to activate the immune function in TME, thus hindering tumor development.

Macrophages play a prominent role in the development of tumors, and M2 macrophages drive tumor invasion, growth and angiogenesis. Therefore, understanding the factors of affecting macrophage polarization is helpful for subsequent tumor therapy targeting macrophages. The cells in TME induce macrophage polarization by regulating the expression of proteins and genes in macrophages, thus driving the development of tumors, and natural products can reverse the undesired polarization. This review provides new ideas for the development of anti-tumor drugs targeting macrophages.

#### **Author contributions**

HZ and XL contributed to the conception of the manuscript. QPL and YYC wrote the draft. QPL and PA drew the graphs. HZ and KR revised the manuscript.

#### **Declaration of competing interest**

The authors have declared that there is no conflict of interests.

#### **Acknowledgments**

This work was supported by funds from National Natural Science Foundation of China (No. 82174023), National Key R & D program for key research project of modernization of traditional Chinese medicine (2019YFC1711602) and Three-year Action Plan for Shanghai TCM Development and Inheritance Program (ZY(2021-2023)- 0401).

# References

- Adams, D.L., Martin, S.S., Alpaugh, R.K., Charpentier, M., Tsai, S., Bergan, R.C., Ogden, I.M., Catalona, W., Chumsri, S., Tang, C.M., Cristofanilli, M., 2014. Circulating giant macrophages as a potential biomarker of solid tumors. *Proc Natl Acad Sci U S A* 111, 3514-3519. <http://dx.doi.org/10.1073/pnas.1320198111>
- Amara, S., Whalen, M., Tiriveedhi, V., 2016. High salt induces anti-inflammatory MPhi2-like phenotype in peripheral macrophages. *Biochem Biophys Rep* 7, 1-9. <http://dx.doi.org/10.1016/j.bbrep.2016.05.009>
- Andon, F.T., Digifico, E., Maeda, A., Erreni, M., Mantovani, A., Alonso, M.J., Allavena, P., 2017. Targeting tumor associated macrophages: The new challenge for nanomedicine. *Semin. Immunol.* 34, 103-113. <http://dx.doi.org/10.1016/j.smim.2017.09.004>
- Azevedo, M., Pina-Vaz, C., Baltazar, F., 2020. Microbes and Cancer: Friends or Faux? *Int. J. Mol. Sci.* 21. <http://dx.doi.org/10.3390/ijms21093115>
- Bai, Y., Yin, K., Su, T., Ji, F., Zhang, S., 2020. CTHRC1 in Ovarian Cancer Promotes M2-Like Polarization of Tumor-Associated Macrophages via Regulation of the STAT6 Signaling Pathway. *Onco Targets Ther.* 13, 5743-5753. <http://dx.doi.org/10.2147/OTT.S250520>
- Balkwill, F., 2004. Cancer and the chemokine network. *Nat. Rev. Cancer* 4, 540-550. <http://dx.doi.org/10.1038/nrc1388>
- Cendrowicz, E., Sas, Z., Bremer, E., Rygiel, T., 2021. The Role of Macrophages in Cancer Development and Therapy. *Cancers (Basel)* 13. <http://dx.doi.org/10.3390/cancers13081946>
- Chen, L.M., Tseng, H.Y., Chen, Y.A., Al Haq, A.T., Hwang, P.A., Hsu, H.L., 2020a. Oligo-Fucoidan Prevents M2 Macrophage Differentiation and HCT116 Tumor Progression. *Cancers (Basel)* 12. <http://dx.doi.org/10.3390/cancers12020421>
- Chen, P., Zuo, H., Xiong, H., Kolar, M.J., Chu, Q., Saghatelian, A., Siegwart, D.J., Wan, Y., 2017. Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. *Proc Natl Acad Sci U S A* 114, 580-585. <http://dx.doi.org/10.1073/pnas.1614035114>
- Chen, R., Lu, X., Li, Z., Sun, Y., He, Z., Li, X., 2020b. Dihydroartemisinin Prevents Progression and Metastasis of Head and Neck Squamous Cell Carcinoma by Inhibiting Polarization of Macrophages in Tumor Microenvironment. *Onco Targets Ther.* 13, 3375-3387. <http://dx.doi.org/10.2147/OTT.S249046>
- Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., Zou, Z., 2019. Tumor-associated macrophages: an accomplice in solid tumor progression. *J. Biomed. Sci.* 26, 78. <http://dx.doi.org/10.1186/s12929-019-0568-z>
- Cheuk, I.W., Chen, J., Siu, M., Ho, J.C., Lam, S.S., Shin, V.Y., Kwong, A., 2022. Resveratrol enhanced chemosensitivity by reversing macrophage polarization in breast cancer. *Clin. Transl. Oncol.* 24, 854-863. <http://dx.doi.org/10.1007/s12094-021-02731-5>
- Dai, E., Han, L., Liu, J., Xie, Y., Kroemer, G., Klionsky, D.J., Zeh, H.J., Kang, R., Wang, J., Tang, D., 2020. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. *Autophagy* 16, 2069-2083. <http://dx.doi.org/10.1080/15548627.2020.1714209>
- Datar, I., Qiu, X., Ma, H., Yeung, M., Aras, S., de la Serna, I., Al-Mulla, F., Thiery, J., Trumbly, R., Fan, X., Cui, H., Yeung, K., 2015. RKIP regulates CCL5 expression to inhibit breast cancer invasion

and metastasis by controlling macrophage infiltration. *Oncotarget* 6, 39050-39061. <http://dx.doi.org/10.18632/oncotarget.5176>

De Vlaeminck, Y., Lecocq, Q., Giron, P., Heirman, C., Geeraerts, X., Bolli, E., Movahedi, K., Massa, S., Schoonooghe, S., Thielemans, K., Goyvaerts, C., Van Ginderachter, J.A., Breckpot, K., 2019. Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages. *J. Control. Release* 299, 107-120. <http://dx.doi.org/10.1016/j.jconrel.2019.02.023>

Deng, X., Zhang, P., Liang, T., Deng, S., Chen, X., Zhu, L., 2015. Ovarian cancer stem cells induce the M2 polarization of macrophages through the PPARgamma and NF-kappaB pathways. *Int. J. Mol. Med.* 36, 449-454. <http://dx.doi.org/10.3892/ijmm.2015.2230>

Ding, X., Sun, X., Cai, H., Wu, L., Liu, Y., Zhao, Y., Zhou, D., Yu, G., Zhou, X., 2021. Engineering Macrophages via Nanotechnology and Genetic Manipulation for Cancer Therapy. *Front. Oncol.* 11, 786913. <http://dx.doi.org/10.3389/fonc.2021.786913>

Fan, L., Xu, C., Ge, Q., Lin, Y., Wong, C., Qi, Y., Ye, B., Lian, Q., Zhuo, W., Si, J., Chen, S., Wang, L., 2021. A. Muciniphila Suppresses Colorectal Tumorigenesis by Inducing TLR2/NLRP3-Mediated M1-Like TAMs. *Cancer immunology research* 9, 1111-1124. <http://dx.doi.org/10.1158/2326-6066.Cir-20-1019>

Feng, J., Yang, H., Zhang, Y., Wei, H., Zhu, Z., Zhu, B., Yang, M., Cao, W., Wang, L., Wu, Z., 2017. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. *Oncogene* 36, 5829-5839. <http://dx.doi.org/10.1038/onc.2017.188>

Gu, J., Sun, R., Tang, D., Liu, F., Chang, X., Wang, Q., 2022. Astragalus mongholicus Bunge-Curcuma aromatica Salisb. suppresses growth and metastasis of colorectal cancer cells by inhibiting M2 macrophage polarization via a Sp1/ZFAS1/miR-153-3p/CCR5 regulatory axis. *Cell biology and toxicology*. <http://dx.doi.org/10.1007/s10565-021-09679-w>

Gulay, K.C.M., Aoshima, K., Maekawa, N., Suzuki, T., Konnai, S., Kobayashi, A., Kimura, T., 2022. Hemangiosarcoma cells induce M2 polarization and PD-L1 expression in macrophages. *Sci. Rep.* 12, 2124. <http://dx.doi.org/10.1038/s41598-022-06203-w>

Herb, M., Schramm, M., 2021. Functions of ROS in Macrophages and Antimicrobial Immunity. *Antioxidants (Basel)* 10. <http://dx.doi.org/10.3390/antiox10020313>

Hernandez-SanMiguel, E., Gargini, R., Cejalvo, T., Segura-Collar, B., Nunez-Hervada, P., Hortiguera, R., Sepulveda-Sanchez, J.M., Hernandez-Lain, A., Perez-Nunez, A., Sanz, E., Sanchez-Gomez, P., 2019. Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma. *Oxid. Med. Cell. Longev.* 2019, 9719730. <http://dx.doi.org/10.1155/2019/9719730>

Huang, C., Ou, R., Chen, X., Zhang, Y., Li, J., Liang, Y., Zhu, X., Liu, L., Li, M., Lin, D., Qiu, J., Liu, G., Zhang, L., Wu, Y., Tang, H., Liu, Y., Liang, L., Ding, Y., Liao, W., 2021a. Tumor cell-derived SPON2 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by activating PYK2 in CRC. *J. Exp. Clin. Cancer Res.* 40, 304. <http://dx.doi.org/10.1186/s13046-021-02108-0>

Huang, Q., Liu, J., Wu, S., Zhang, X., Xiao, Z., Liu, Z., Du, W., 2021b. Spi-B Promotes the Recruitment of Tumor-Associated Macrophages via Enhancing CCL4 Expression in Lung Cancer. *Front. Oncol.* 11, 659131. <http://dx.doi.org/10.3389/fonc.2021.659131>

Huang, Y.H., Cai, K., Xu, P.P., Wang, L., Huang, C.X., Fang, Y., Cheng, S., Sun, X.J., Liu, F., Huang, J.Y., Ji, M.M., Zhao, W.L., 2021c. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via



548 FBXW7-NOTCH-CCL2/CSF1 axis. *Signal Transduct Target Ther* 6, 10.  
 549 <http://dx.doi.org/10.1038/s41392-020-00437-8>  
 550 Jeong, S.K., Yang, K., Park, Y.S., Choi, Y.J., Oh, S.J., Lee, C.W., Lee, K.Y., Jeong, M.H., Jo, W.S.,  
 551 2014. Interferon gamma induced by resveratrol analog, HS-1793, reverses the properties of tumor  
 552 associated macrophages. *Int. Immunopharmacol.* 22, 303-310.  
 553 <http://dx.doi.org/10.1016/j.intimp.2014.07.004>  
 554 Jia, W., Luo, S., Lai, G., Li, S., Huo, S., Li, M., Zeng, X., 2021. Homogeneous polyporus  
 555 polysaccharide inhibits bladder cancer by polarizing macrophages to M1 subtype in tumor  
 556 microenvironment. *BMC complementary medicine and therapies* 21, 150.  
 557 <http://dx.doi.org/10.1186/s12906-021-03318-x>  
 558 Jiang, Z., Zhang, Y., Zhang, Y., Jia, Z., Zhang, Z., Yang, J., 2021. Cancer derived exosomes induce  
 559 macrophages immunosuppressive polarization to promote bladder cancer progression. *Cell*  
 560 *Commun Signal* 19, 93. <http://dx.doi.org/10.1186/s12964-021-00768-1>  
 561 Johdi, N.A., Sukor, N.F., 2020. Colorectal Cancer Immunotherapy: Options and Strategies. *Front.*  
 562 *Immunol.* 11, 1624. <http://dx.doi.org/10.3389/fimmu.2020.01624>  
 563 Kenny, P., Lee, G., Bissell, M., 2007. Targeting the tumor microenvironment. *Frontiers in*  
 564 *bioscience : a journal and virtual library* 12, 3468-3474. <http://dx.doi.org/10.2741/2327>  
 565 Kim, Y.K., Kim, S.E., Chang Park, H., Hwang, J.H., Lee, H.T., 2020. Human recombinant IL-10  
 566 reduces xenogenic cytotoxicity via macrophage M2 polarization. *Biochem Biophys Rep* 24, 100857.  
 567 <http://dx.doi.org/10.1016/j.bbrep.2020.100857>  
 568 Le, Y., Gao, H., Richards, W., Zhao, L., Bleday, R., Clancy, T., Zhu, Z., 2020. VentX expression in  
 569 tumor-associated macrophages promotes phagocytosis and immunity against pancreatic cancers.  
 570 *JCI Insight* 5. <http://dx.doi.org/10.1172/jci.insight.137088>  
 571 Lecoultre, M., Dutoit, V., Walker, P.R., 2020. Phagocytic function of tumor-associated macrophages  
 572 as a key determinant of tumor progression control: a review. *J Immunother Cancer* 8.  
 573 <http://dx.doi.org/10.1136/jitc-2020-001408>  
 574 Li, J., Cai, H., Sun, H., Qu, J., Zhao, B., Hu, X., Li, W., Qian, Z., Yu, X., Kang, F., Wang, W., Zou,  
 575 Z., Gu, B., Xu, K., 2020. Extracts of *Cordyceps sinensis* inhibit breast cancer growth through  
 576 promoting M1 macrophage polarization via NF- $\kappa$ B pathway activation. *J. Ethnopharmacol.* 260,  
 577 112969. <http://dx.doi.org/10.1016/j.jep.2020.112969>  
 578 Li, J., Wang, S., Wang, N., Zheng, Y., Yang, B., Wang, X., Zhang, J., Pan, B., Wang, Z., 2021.  
 579 Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg  
 580 differentiation and infiltration. *Cell communication and signaling : CCS* 19, 89.  
 581 <http://dx.doi.org/10.1186/s12964-021-00775-2>  
 582 Li, L.Y., Yin, K.M., Bai, Y.H., Zhang, Z.G., Di, W., Zhang, S., 2019. CTHRC1 promotes M2-like  
 583 macrophage recruitment and myometrial invasion in endometrial carcinoma by integrin-Akt  
 584 signaling pathway. *Clin Exp Metastasis* 36, 351-363. [http://dx.doi.org/10.1007/s10585-019-09971-](http://dx.doi.org/10.1007/s10585-019-09971-4)  
 585 [4](http://dx.doi.org/10.1007/s10585-019-09971-4)  
 586 Li, N., Qin, J., Lan, L., Zhang, H., Liu, F., Wu, Z., Ni, H., Wang, Y., 2015. PTEN inhibits  
 587 macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1  
 588 synergism. *Cancer Biol. Ther.* 16, 297-306. <http://dx.doi.org/10.1080/15384047.2014.1002353>  
 589 Li, Y., Cai, L., Wang, H., Wu, P., Gu, W., Chen, Y., Hao, H., Tang, K., Yi, P., Liu, M., Miao, S., Ye,  
 590 D., 2011. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide  
 591 receptor-2. *Oncogene* 30, 3887-3899. <http://dx.doi.org/10.1038/onc.2011.112>

Liu, F., Liang, Y., Sun, R., Yang, W., Liang, Z., Gu, J., Zhao, F., Tang, D., 2022a. Astragalus mongholicus Bunge and Curcuma aromatica Salisb. inhibits liver metastasis of colon cancer by regulating EMT via the CXCL8/CXCR2 axis and PI3K/AKT/mTOR signaling pathway. Chin. Med. 17, 91. <http://dx.doi.org/10.1186/s13020-022-00641-4>

Liu, F., Ran, F., He, H., Chen, L., 2020. Astragaloside IV Exerts Anti-tumor Effect on Murine Colorectal Cancer by Re-educating Tumor-Associated Macrophage. Arch. Immunol. Ther. Exp. (Warsz.) 68, 33. <http://dx.doi.org/10.1007/s00005-020-00598-y>

Liu, W., Gao, Y., Zhou, Y., Yu, F., Li, X., Zhang, N., 2022b. Mechanism of Cordyceps sinensis and its Extracts in the Treatment of Diabetic Kidney Disease: A Review. Front. Pharmacol. 13, 881835. <http://dx.doi.org/10.3389/fphar.2022.881835>

Liu, Y., Wang, R., 2020. Immunotherapy Targeting Tumor-Associated Macrophages. Frontiers in medicine 7, 583708. <http://dx.doi.org/10.3389/fmed.2020.583708>

Locati, M., Mantovani, A., Sica, A., 2013. Macrophage activation and polarization as an adaptive component of innate immunity. Advances in immunology 120, 163-184. <http://dx.doi.org/10.1016/b978-0-12-417028-5.00006-5>

Low-Marchelli, J.M., Ardi, V.C., Vizcarra, E.A., van Rooijen, N., Quigley, J.P., Yang, J., 2013. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res. 73, 662-671. <http://dx.doi.org/10.1158/0008-5472.CAN-12-0653>

Lu, C., Shi, W., Hu, W., Zhao, Y., Zhao, X., Dong, F., Xin, Y., Peng, T., Liu, C., 2022. Endoplasmic reticulum stress promotes breast cancer cells to release exosomes circ\_0001142 and induces M2 polarization of macrophages to regulate tumor progression. Pharmacol. Res. 177, 106098. <http://dx.doi.org/10.1016/j.phrs.2022.106098>

Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., Shi, S., 2021. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol. Cancer 20, 131. <http://dx.doi.org/10.1186/s12943-021-01428-1>

Mu, J., Sun, P., Ma, Z., Sun, P., 2019. BRD4 promotes tumor progression and NF-kappaB/CCL2-dependent tumor-associated macrophage recruitment in GIST. Cell Death Dis. 10, 935. <http://dx.doi.org/10.1038/s41419-019-2170-4>

Mu, X., Shi, W., Xu, Y., Xu, C., Zhao, T., Geng, B., Yang, J., Pan, J., Hu, S., Zhang, C., Zhang, J., Wang, C., Shen, J., Che, Y., Liu, Z., Lv, Y., Wen, H., You, Q., 2018. Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer. Cell Cycle 17, 428-438. <http://dx.doi.org/10.1080/15384101.2018.1444305>

Muller, A.K., Kohler, U.A., Trzebanski, S., Vinik, Y., Raj, H.M., Girault, J.A., Ben-Chetrit, N., Maraver, A., Jung, S., Lev, S., 2022. Mouse Modeling Dissecting Macrophage-Breast Cancer Communication Uncovered Roles of PYK2 in Macrophage Recruitment and Breast Tumorigenesis. Adv Sci (Weinh), e2105696. <http://dx.doi.org/10.1002/advs.202105696>

Orillion, A., Damayanti, N.P., Shen, L., Adelaiye-Ogala, R., Affronti, H., Elbanna, M., Chintala, S., Ciesielski, M., Fontana, L., Kao, C., Elzey, B.D., Ratliff, T.L., Nelson, D.E., Smiraglia, D., Abrams, S.I., Pili, R., 2018. Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy. Clin Cancer Res 24, 6383-6395. <http://dx.doi.org/10.1158/1078-0432.CCR-18-0980>

Pan, Y., Yu, Y., Wang, X., Zhang, T., 2020. Tumor-Associated Macrophages in Tumor Immunity. Front. Immunol. 11, 583084. <http://dx.doi.org/10.3389/fimmu.2020.583084>

Prenen, H., Mazzone, M., 2019. Tumor-associated macrophages: a short compendium. *Cell Mol Life Sci* 76, 1447-1458. <http://dx.doi.org/10.1007/s00018-018-2997-3>

Qian, B., Pollard, J., 2010. Macrophage diversity enhances tumor progression and metastasis. *Cell* 141, 39-51. <http://dx.doi.org/10.1016/j.cell.2010.03.014>

Qiu, S.Q., Waaijer, S.J.H., Zwager, M.C., de Vries, E.G.E., van der Vegt, B., Schroder, C.P., 2018. Tumor-associated macrophages in breast cancer: Innocent bystander or important player? *Cancer Treat. Rev.* 70, 178-189. <http://dx.doi.org/10.1016/j.ctrv.2018.08.010>

Rai, R., Vishvakarma, N., Mohapatra, T., Singh, S., 2012. Augmented macrophage differentiation and polarization of tumor-associated macrophages towards M1 subtype in listeria-administered tumor-bearing host. *Journal of immunotherapy (Hagerstown, Md. : 1997)* 35, 544-554. <http://dx.doi.org/10.1097/CJI.0b013e3182661afa>

Relation, T., Yi, T., Guess, A.J., La Perle, K., Otsuru, S., Hasgur, S., Dominici, M., Breuer, C., Horwitz, E.M., 2018. Intratumoral Delivery of Interferongamma-Secreting Mesenchymal Stromal Cells Repolarizes Tumor-Associated Macrophages and Suppresses Neuroblastoma Proliferation In Vivo. *Stem Cells* 36, 915-924. <http://dx.doi.org/10.1002/stem.2801>

Robertson, I., Wai Hau, T., Sami, F., Sajid Ali, M., Badgujar, V., Murtuja, S., Saquib Hasnain, M., Khan, A., Majeed, S., Tahir Ansari, M., 2022. The science of resveratrol, formulation, pharmacokinetic barriers and its chemotherapeutic potential. *Int. J. Pharm.* 618, 121605. <http://dx.doi.org/10.1016/j.ijpharm.2022.121605>

Roca, H., Varsos, Z.S., Sud, S., Craig, M.J., Ying, C., Pienta, K.J., 2009. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. *J Biol Chem* 284, 34342-34354. <http://dx.doi.org/10.1074/jbc.M109.042671>

Saeedifar, A.M., Mosayebi, G., Ghazavi, A., Bushehri, R.H., Ganji, A., 2021. Macrophage polarization by phytotherapy in the tumor microenvironment. *Phytother. Res.* 35, 3632-3648. <http://dx.doi.org/10.1002/ptr.7058>

Salmaninejad, A., Valilou, S.F., Soltani, A., Ahmadi, S., Abarghan, Y.J., Rosengren, R.J., Sahebkar, A., 2019. Tumor-associated macrophages: role in cancer development and therapeutic implications. *Cell. Oncol. (Dordr.)* 42, 591-608. <http://dx.doi.org/10.1007/s13402-019-00453-z>

Sawant, S., Patil, S., Gupta, V., Kunda, N., 2020. Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment. *Int. J. Mol. Sci.* 21. <http://dx.doi.org/10.3390/ijms21207575>

Seong, J.B., Kim, B., Kim, S., Kim, M.H., Park, Y.H., Lee, Y., Lee, H.J., Hong, C.W., Lee, D.S., 2021. Macrophage peroxiredoxin 5 deficiency promotes lung cancer progression via ROS-dependent M2-like polarization. *Free Radic. Biol. Med.* 176, 322-334. <http://dx.doi.org/10.1016/j.freeradbiomed.2021.10.010>

Shan, M., Qin, J., Jin, F., Han, X., Guan, H., Li, X., Zhang, J., Zhang, H., Wang, Y., 2017. Autophagy suppresses isoprenaline-induced M2 macrophage polarization via the ROS/ERK and mTOR signaling pathway. *Free Radic. Biol. Med.* 110, 432-443. <http://dx.doi.org/10.1016/j.freeradbiomed.2017.05.021>

Shu, Y., Qin, M., Song, Y., Tang, Q., Huang, Y., Shen, P., Lu, Y., 2020. M2 polarization of tumor-associated macrophages is dependent on integrin beta3 via peroxisome proliferator-activated receptor-gamma up-regulation in breast cancer. *Immunology* 160, 345-356. <http://dx.doi.org/10.1111/imm.13196>

Slack, R.J., Macdonald, S.J.F., Roper, J.A., Jenkins, R.G., Hatley, R.J.D., 2022. Emerging therapeutic opportunities for integrin inhibitors. *Nat. Rev. Drug Discov.* 21, 60-78. <http://dx.doi.org/10.1038/s41573-021-00284-4>

Slettenaar, V.I., Wilson, J.L., 2006. The chemokine network: a target in cancer biology? *Adv Drug Deliv Rev* 58, 962-974. <http://dx.doi.org/10.1016/j.addr.2006.03.012>

Song, J., Yang, P., Li, X., Zhu, X., Liu, M., Duan, X., Liu, R., 2021a. Esophageal Cancer-Derived Extracellular Vesicle miR-21-5p Contributes to EMT of ESCC Cells by Disorganizing Macrophage Polarization. *Cancers (Basel)* 13. <http://dx.doi.org/10.3390/cancers13164122>

Song, M., Li, Z.H., Gu, H.S., Tang, R.Y., Zhang, R., Zhu, Y.L., Liu, J.L., Zhang, J.J., Wang, L.Y., 2021b. Ganoderma lucidum Spore Polysaccharide Inhibits the Growth of Hepatocellular Carcinoma Cells by Altering Macrophage Polarity and Induction of Apoptosis. *J Immunol Res* 2021, 6696606. <http://dx.doi.org/10.1155/2021/6696606>

Suarez-Lopez, L., Kong, Y.W., Sriram, G., Patterson, J.C., Rosenberg, S., Morandell, S., Haigis, K.M., Yaffe, M.B., 2020. MAPKAP Kinase-2 Drives Expression of Angiogenic Factors by Tumor-Associated Macrophages in a Model of Inflammation-Induced Colon Cancer. *Front. Immunol.* 11, 607891. <http://dx.doi.org/10.3389/fimmu.2020.607891>

Tan, J., Yang, L., Zhao, H., Ai, Y., Ren, L., Zhang, F., Dong, W., Shi, R., Sun, D., Feng, Y., 2022. The role of NFATc1/c-myc/PKM2/IL-10 axis in activating cervical cancer tumor-associated M2 macrophage polarization to promote cervical cancer progression. *Exp Cell Res*, 113052. <http://dx.doi.org/10.1016/j.yexcr.2022.113052>

Tao, S., Chen, Q., Lin, C., Dong, H., 2020. Linc00514 promotes breast cancer metastasis and M2 polarization of tumor-associated macrophages via Jagged1-mediated notch signaling pathway. *J. Exp. Clin. Cancer Res.* 39, 191. <http://dx.doi.org/10.1186/s13046-020-01676-x>

Végran, F., Boidot, R., Michiels, C., Sonveaux, P., Feron, O., 2011. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. *Cancer Res.* 71, 2550-2560. <http://dx.doi.org/10.1158/0008-5472.Can-10-2828>

Wang, H., Yung, M.M.H., Ngan, H.Y.S., Chan, K.K.L., Chan, D.W., 2021a. The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression. *Int. J. Mol. Sci.* 22. <http://dx.doi.org/10.3390/ijms22126560>

Wang, L., Wu, W., Zhu, X., Ng, W., Gong, C., Yao, C., Ni, Z., Yan, X., Fang, C., Zhu, S., 2019. The Ancient Chinese Decoction Yu-Ping-Feng Suppresses Orthotopic Lewis Lung Cancer Tumor Growth Through Increasing M1 Macrophage Polarization and CD4(+) T Cell Cytotoxicity. *Front. Pharmacol.* 10, 1333. <http://dx.doi.org/10.3389/fphar.2019.01333>

Wang, X., Gao, S., Song, L., Liu, M., Sun, Z., Liu, J., 2021b. Astragaloside IV antagonizes M2 phenotype macrophage polarization-evoked ovarian cancer cell malignant progression by suppressing the HMGB1-TLR4 axis. *Mol Immunol* 130, 113-121. <http://dx.doi.org/10.1016/j.molimm.2020.11.014>

Wang, X., Wang, J., Zhao, J., Wang, H., Chen, J., Wu, J., 2022. HMGA2 facilitates colorectal cancer progression via STAT3-mediated tumor-associated macrophage recruitment. *Theranostics* 12, 963-975. <http://dx.doi.org/10.7150/thno.65411>

Wei, R., Zhu, W.W., Yu, G.Y., Wang, X., Gao, C., Zhou, X., Lin, Z.F., Shao, W.Q., Wang, S.H., Lu, M., Qin, L.X., 2021. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma. *Int J Cancer* 148, 1233-1244. <http://dx.doi.org/10.1002/ijc.33371>

Wolf-Dennen, K., Gordon, N., Kleinerman, E.S., 2020. Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. *Oncoimmunology* 9, 1747677. <http://dx.doi.org/10.1080/2162402X.2020.1747677>

Woo, S.M., Choi, Y.K., Cho, S.G., Park, S., Ko, S.G., 2013. A New Herbal Formula, KSG-002, Suppresses Breast Cancer Growth and Metastasis by Targeting NF- kappa B-Dependent TNF alpha Production in Macrophages. *Evid. Based Complement. Alternat. Med.* 2013, 728258. <http://dx.doi.org/10.1155/2013/728258>

Wu, J.Y., Huang, T.W., Hsieh, Y.T., Wang, Y.F., Yen, C.C., Lee, G.L., Yeh, C.C., Peng, Y.J., Kuo, Y.Y., Wen, H.T., Lin, H.C., Hsiao, C.W., Wu, K.K., Kung, H.J., Hsu, Y.J., Kuo, C.C., 2020. Cancer-Derived Succinate Promotes Macrophage Polarization and Cancer Metastasis via Succinate Receptor. *Mol Cell* 77, 213-227 e215. <http://dx.doi.org/10.1016/j.molcel.2019.10.023>

Wu, R.S., Lin, J., Xing, Y.M., Gao, W.L., Jiang, Y.X., Chen, L.X., Zhang, X.P., Dai, Z.L., 2022. OVOL2 inhibits macrophage M2 polarization by regulating IL-10 transcription, and thus inhibits the tumor metastasis by modulating the tumor microenvironment. *Immunol Lett* 242, 17-26. <http://dx.doi.org/10.1016/j.imlet.2021.05.004>

Xia, L., Huang, W., Tian, D., Zhang, L., Qi, X., Chen, Z., Shang, X., Nie, Y., Wu, K., 2014. Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression. *Hepatology* 59, 958-973. <http://dx.doi.org/10.1002/hep.26735>

Xiao, X., Li, Y., Wang, Y., Zhang, Y., Chen, J., Liu, W., Tang, J., Yue, F., Yang, J., 2022. Dihydroartemisinin inhibits Lewis Lung carcinoma progression by inducing macrophages M1 polarization via AKT/mTOR pathway. *Int. Immunopharmacol.* 103, 108427. <http://dx.doi.org/10.1016/j.intimp.2021.108427>

Xie, L., Yang, Y., Meng, J., Wen, T., Liu, J., Xu, H., 2019. Cationic polysaccharide spermine-pullulan drives tumor associated macrophage towards M1 phenotype to inhibit tumor progression. *Int J Biol Macromol* 123, 1012-1019. <http://dx.doi.org/10.1016/j.ijbiomac.2018.11.089>

Xing, X., Wang, Y., Zhang, X., Gao, X., Li, M., Wu, S., Zhao, Y., Chen, J., Gao, D., Chen, R., Ren, Z., Zhang, K., Cui, J., 2021. Matrix stiffness-mediated effects on macrophages polarization and their LOXL2 expression. *FEBS J.* 288, 3465-3477. <http://dx.doi.org/10.1111/febs.15566>

Xu, C., Fan, L., Lin, Y., Shen, W., Qi, Y., Zhang, Y., Chen, Z., Wang, L., Long, Y., Hou, T., Si, J., Chen, S., 2021a. *Fusobacterium nucleatum* promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. *Gut Microbes* 13, 1980347. <http://dx.doi.org/10.1080/19490976.2021.1980347>

Xu, H., Li, D., Ma, J., Zhao, Y., Xu, L., Tian, R., Liu, Y., Sun, L., Su, J., 2021b. The IL-33/ST2 axis affects tumor growth by regulating mitophagy in macrophages and reprogramming their polarization. *Cancer Biol Med* 18, 172-183. <http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0211>

Xu, L., Xie, X., Li, X., Duan, W., Qiu, L., Liu, H., Luo, Y., 2022. Inflammatory level under different p53 mutation status and the regulation role of curcumin in tumor microenvironment. *Immunobiology* 227, 152177. <http://dx.doi.org/10.1016/j.imbio.2022.152177>

Yao, X., He, Z., Qin, C., Deng, X., Bai, L., Li, G., Shi, J., 2020. SLC2A3 promotes macrophage infiltration by glycolysis reprogramming in gastric cancer. *Cancer Cell Int.* 20, 503. <http://dx.doi.org/10.1186/s12935-020-01599-9>

Yasunaga, J., Matsuoka, M., 2018. Oncogenic spiral by infectious pathogens: Cooperation of multiple factors in cancer development. *Cancer Sci.* 109, 24-32. <http://dx.doi.org/10.1111/cas.13443>

Ye, J., Yang, Y., Dong, W., Gao, Y., Meng, Y., Wang, H., Li, L., Jin, J., Ji, M., Xia, X., Chen, X., Jin, Y., Liu, Y., 2019. Drug-free mannosylated liposomes inhibit tumor growth by promoting the polarization of tumor-associated macrophages. *Int J Nanomedicine* 14, 3203-3220. <http://dx.doi.org/10.2147/IJN.S207589>

Yin, S., Wang, N., Riabov, V., Mossel, D.M., Larionova, I., Schledzewski, K., Trofimova, O., Sevastyanova, T., Zajakina, A., Schmuttermaier, C., Gratchev, A., Flatley, A., Kremmer, E., Zavyalova, M., Cherdyntseva, N., Simon-Keller, K., Marx, A., Kluter, H., Goerdts, S., Kzhyshkowska, J., 2020. SI-CLP inhibits the growth of mouse mammary adenocarcinoma by preventing recruitment of tumor-associated macrophages. *Int J Cancer* 146, 1396-1408. <http://dx.doi.org/10.1002/ijc.32685>

Zhang, A., Qian, Y., Ye, Z., Chen, H., Xie, H., Zhou, L., Shen, Y., Zheng, S., 2017. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. *Cancer Med* 6, 463-470. <http://dx.doi.org/10.1002/cam4.993>

Zhang, L., Li, S., 2020. Lactic acid promotes macrophage polarization through MCT-HIF1 $\alpha$  signaling in gastric cancer. *Exp Cell Res* 388, 111846. <http://dx.doi.org/10.1016/j.yexcr.2020.111846>

Zhang, Q., Wang, H., Mao, C., Sun, M., Dominah, G., Chen, L., Zhuang, Z., 2018a. Fatty acid oxidation contributes to IL-1 $\beta$  secretion in M2 macrophages and promotes macrophage-mediated tumor cell migration. *Mol Immunol* 94, 27-35. <http://dx.doi.org/10.1016/j.molimm.2017.12.011>

Zhang, Q., Wang, J., Yadav, D.K., Bai, X., Liang, T., 2021a. Glucose Metabolism: The Metabolic Signature of Tumor Associated Macrophage. *Front. Immunol.* 12, 702580. <http://dx.doi.org/10.3389/fimmu.2021.702580>

Zhang, Y.L., Li, Q., Yang, X.M., Fang, F., Li, J., Wang, Y.H., Yang, Q., Zhu, L., Nie, H.Z., Zhang, X.L., Feng, M.X., Jiang, S.H., Tian, G.A., Hu, L.P., Lee, H.Y., Lee, S.J., Xia, Q., Zhang, Z.G., 2018b. SPON2 Promotes M1-like Macrophage Recruitment and Inhibits Hepatocellular Carcinoma Metastasis by Distinct Integrin-Rho GTPase-Hippo Pathways. *Cancer Res.* 78, 2305-2317. <http://dx.doi.org/10.1158/0008-5472.CAN-17-2867>

Zhang, Z., Zhu, Y., Xu, D., Li, T., Li, J., Xiao, Z., Chen, M., Yang, X., Jia, H., Dong, Q., Qin, L., 2021b. IFN- $\alpha$  facilitates the effect of sorafenib via shifting the M2-like polarization of TAM in hepatocellular carcinoma. *American journal of translational research* 13, 301-313.

Zhao, T., Mu, X., You, Q., 2017. Succinate: An initiator in tumorigenesis and progression. *Oncotarget* 8, 53819-53828. <http://dx.doi.org/10.18632/oncotarget.17734>

Zhao, Y., Wang, D., Xu, T., Liu, P., Cao, Y., Wang, Y., Yang, X., Xu, X., Wang, X., Niu, H., 2015. Bladder cancer cells re-educate TAMs through lactate shuttling in the microfluidic cancer microenvironment. *Oncotarget* 6, 39196-39210. <http://dx.doi.org/10.18632/oncotarget.5538>

Zheng, J., Yang, M., Shao, J., Miao, Y., Han, J., Du, J., 2013. Chemokine receptor CX3CR1 contributes to macrophage survival in tumor metastasis. *Mol. Cancer* 12, 141. <http://dx.doi.org/10.1186/1476-4598-12-141>

## Legends

**Figure 1** Classification of macrophages. Macrophages can be divided into M1 type and M2 type. IFN- $\gamma$  induces the polarization of macrophages into M1 with anti-tumor activity, while IL-4/IL-13 promotes the polarization of macrophages into M2 with pro-tumor activity. In addition, M2 macrophages can be subdivided into M2a, M2b, M2c and M2d under different stimuli. M2a and M2b play an immune regulatory role and drive Th2 response, M2c inhibits immune response and promotes tissue remodeling, while M2d facilitates tumor progression.

**Figure 2** Effects of exosomes from cancer cells on polarization of macrophages. Cancer cells promote M2 polarization by secreting exosomes to activate several signaling pathways in macrophages.

**Figure 3** Metabolites from cancer cells enhance the polarization of macrophages. Succinic acid and lactic acid from tumor cells promote M2 polarization of macrophages.

**Figure 4** Chemokines secreted by cancer cells enhance the recruitment of macrophages. Tumor cells secrete a series of cytokines that encourage the recruitment of macrophages to the tumor site.

**Figure 5** The regulative mechanism of macrophage M2 polarization.

**Table 1** Regulation of macrophage polarization and recruitment

**Table 2** Effects of tumor cells on macrophage polarization and recruitment

**Table 3** Natural products and drugs targeting macrophages in TME

Table 1 Regulation of macrophage polarization and recruitment

| Cancer                        | Protein       | Target                               | Effect  | Model                              | Refs                        |
|-------------------------------|---------------|--------------------------------------|---|------------------------------------|-----------------------------|
| PDA                           | VentX         | -                                    | Promoting phagocytosis of TAMs  | <i>In vitro</i>                    | (Le et al., 2020)           |
| Breast cancer                 | integrin b3   | PPARc                                | Promoting M2 polarization   | <i>In vivo</i> and <i>in vitro</i> | (Shu et al., 2020)          |
| Hepatocellular carcinoma      | SPON2         | SPON2/ $\alpha$ 4 $\beta$ 1 integrin | Promoting M1 recruitment  | <i>In vivo</i> and <i>in vitro</i> | (Zhang et al., 2018b)       |
| Lung cancer                   | Prx5          | ROS                                  | Inhibiting M2 polarization  | <i>In vivo</i> and <i>in vitro</i> | (Seong et al., 2021)        |
| Colon cancer                  | MK2           | CXCL-12/SDF-1                        | Promoting angiogenesis  | <i>In vivo</i> and <i>in vitro</i> | (Suarez-Lopez et al., 2020) |
| Colon cancer                  | CX3CR1        | -                                    | Promoting TAMs apoptosis  | <i>In vivo</i> and <i>in vitro</i> | (Zheng et al., 2013)        |
| Breast cancer                 | PTEN          | CCL2                                 | Inhibiting M2 polarization  | <i>In vitro</i>                    | (Li et al., 2015)           |
| -                             | CCL2 and IL-6 | caspase-8                            | Promoting M2 polarization   | <i>In vitro</i>                    | (Roca et al., 2009)         |
| Breast cancer                 | OVOL2         | IL-10                                | Inhibiting M2 polarization  | <i>In vivo</i>                     | (Wu et al., 2022)           |
| Lewis lung cancer             | DC-SIGN       | -                                    | Promoting M2 polarization   | <i>In vitro</i>                    | (Yan et al., 2016)          |
| Serous ovarian cancer         | ALOX5AP       | -                                    | Promoting M2 polarization and recruitment   | <i>In vitro</i>                    | (Ye et al., 2021)           |
| Colon cancer                  | ICAM-1        | PI3K/AKT                             | Promoting M2 polarization   | <i>In vivo</i> and <i>in vitro</i> | (Yang et al., 2015)         |
| Renal carcinoma               | AIM2          | Inflammasome signaling               | Enhancing TAMs polarization switch from anti-inflammatory M2 to pro-inflammatory M1 | <i>In vivo</i> and <i>in vitro</i> | (Chai et al., 2021)         |
| Triple-negative breast cancer | SMS2          | -                                    | Promoting M2 polarization   | <i>In vivo</i> and <i>in vitro</i> | (Deng et al., 2021b)        |
| Breast cancer                 | KLF14         | RhoA/Rock/STAT3                      | Inhibiting M2 polarization  | <i>In vivo</i> and <i>in vitro</i> | (Chu et al., 2022)          |
| Colorectal cancer             | -             | TLR-4/MyD88/NF- $\kappa$ B           | prompting M1 polarization   | <i>In vivo</i> and <i>in vitro</i> | (Andreuzzi et al., 2022)    |
| Endometrial cancer            | CTHRC1        | CTHRC1-integrin $\beta$ 3-Akt        | Promoting M2 recruitment  | <i>In vitro</i>                    | (Li et al., 2019)           |
| Ovarian Cancer                | CTHRC1        | STAT6                                | Promoting M2 polarization   | <i>In vitro</i>                    | (Bai et al., 2020)          |
| Colon cancer                  | C5aR          | NF-Kb                                | Promoting M2 polarization and infiltration  | <i>In vivo</i> and <i>in vitro</i> | (Piao et al., 2018)         |



Table 2 Effects of tumor cells on macrophage polarization and recruitment

| Cancer                   | Exosome      | Target                         | Effect   | Model                              | Refs                     |
|--------------------------|--------------|--------------------------------|--|------------------------------------|--------------------------|
| Breast cancer            | Gpr132       | -                              | Promoting M2 polarization  | <i>In vivo</i> and <i>in vitro</i> | (Chen et al., 2017)      |
| Gastric cancer           | SLC2A3       | -                              | Promoting M2 polarization and infiltration                           | <i>In vivo</i> and <i>in vitro</i> | (Yao et al., 2020)       |
| Breast cancer            | miR-375      | SREBP2                         | Regulating metabolism of macrophages                                 | <i>In vivo</i> and <i>in vitro</i> | (Frank et al., 2021)     |
| Gallbladder cancer       | Leptin       | STAT3                          | Promoting M2 polarization  | <i>In vitro</i>                    | (Zhao et al., 2022b)     |
| Breast cancer            | Leptin       | Ob/ObR                         | Promoting recruitment of TAMs  | <i>In vivo</i> and <i>in vitro</i> | (Gelsomino et al., 2020) |
| Bladder cancer           | miRNA        | PTEN/AKT/STAT3/6               | Inducing macrophage polarization into immunosuppressive phenotype    | <i>In vivo</i> and <i>in vitro</i> | (Jiang et al., 2021)     |
| Esophageal cancer        | miR-21-5p    | PTEN/AKT/STAT6                 | Promoting M2 polarization  | <i>In vitro</i>                    | (Song et al., 2021a)     |
| Breast cancer            | circ_0001142 | circ_0001142/miR-361-3p/PIK3CB | Promoting M2 polarization  | <i>In vitro</i>                    | (Lu et al., 2022)        |
| Breast cancer            | Linc00514    | NOTCH                          | Promoting M2 polarization  | <i>In vivo</i> and <i>in vitro</i> | (Tao et al., 2020)       |
| Hepatocellular carcinoma | FoxQ1        | VersicanV1/CCL2                | Promoting recruitment of macrophages                                 | <i>In vivo</i> and <i>in vitro</i> | (Xia et al., 2014)       |
| Breast cancer            | PYK2         | Notch1                         | Regulating monocyte recruitment, polarization and tumor angiogenesis | <i>In vivo</i> and <i>in vitro</i> | (Muller et al., 2022)    |
| Breast cancer            | SI-CLP       | -                              | Inhibiting recruitment of macrophages                                | <i>In vivo</i> and <i>in vitro</i> | (Yin et al., 2020)       |
| Lung cancer              | Spi-B        | -                              | Promoting TAM recruitment to TEM                                     | <i>In vivo</i> and <i>in vitro</i> | (Huang et al., 2021b)    |
| Colorectal cancer        | HMGA2        | STAT3                          | Promoting recruitment of macrophages                                 | <i>In vivo</i> and <i>in vitro</i> | (Wang et al., 2022)      |

|                                |              |                               |  |                             |                              |
|--------------------------------|--------------|-------------------------------|--|-----------------------------|------------------------------|
| Breast cancer                  | Twist1       | -                             | Promoting recruitment of macrophages               | <i>In vivo and in vitro</i> | (Low-Marchelli et al., 2013) |
| Breast cancer                  | RKIP         | -                             | Inhibiting macrophage infiltration into tumor site | <i>In vivo and in vitro</i> | (Datar et al., 2015)         |
| Triple-negative breast cancer  | RKIP         | -                             | Inhibiting TAMs infiltration into tumor site       | <i>In vivo and in vitro</i> | (Frankenberger et al., 2015) |
| Nasopharyngeal carcinoma       | ISG15        | LFA-1-SRC-CCL18               | Promoting M2 polarization                          | <i>In vitro</i>             | (Chen et al., 2020c)         |
| Gastrointestinal stromal tumor | BRD4         | NF- $\kappa$ B                | Promoting recruitment of M2 macrophages            | <i>In vitro</i>             | (Mu et al., 2019)            |
| Breast cancer                  | CITED2       | -                             | Promoting recruitment of macrophages               | <i>In vivo and in vitro</i> | (Jayaraman et al., 2018)     |
| Glioblastoma                   | FGL2         | CD16/SyK/PI3K/HIF1 $\alpha$   | Inducing macrophages to secrete chemokines         | <i>In vitro</i>             | (Yan et al., 2021)           |
| Colorectal cancer              | SPON2        | SPON2/integrin $\beta$ 1/PYK2 | Promoting TAMs infiltration and M2 polarization    | <i>In vivo and in vitro</i> | (Huang et al., 2021a)        |
| DLBCL                          | CREBBP/EP300 | FBXW7-NOTCH-CCL2/CSF1         | Promoting M2 polarization                          | <i>In vivo and in vitro</i> | (Huang et al., 2021c)        |
| PDA                            | KRAS         | Ferroptosis                   | Promoting M2 polarization                          | <i>In vitro</i>             | (Dai et al., 2020)           |
| Lung cancer                    | p53          | -                             | Promoting M2 polarization                          | <i>In vivo and in vitro</i> | (Xu et al., 2022a)           |
| Breast cancer                  | Annexin 1    | FPR2                          | Promoting M2 polarization                          | <i>In vivo and in vitro</i> | (Moraes et al., 2017)        |
| Lewis lung cancer              | TNFSF15      | STAT1, STAT3 and STAT6        | Promoting M1 infiltration and polarization         | <i>In vivo and in vitro</i> | (Zhao et al., 2022a)         |
| Hemangiosarcoma                | -            | -                             | Promoting M2 polarization                          | <i>In vivo and in vitro</i> | (Gulay et al., 2022)         |
| Gastric cancer                 | PINK1        | -                             | Promoting M2 polarization                          | <i>In vivo and in vitro</i> | (Xu et al., 2022b)           |
| -                              | PAI-1        | p38MAPK and NF- $\kappa$ B    | Promoting M2 polarization                          | <i>In vivo and in vitro</i> | (Kubala et al., 2018)        |

|                                    |               |                     |   |                             |                             |
|------------------------------------|---------------|---------------------|---|-----------------------------|-----------------------------|
| Melanoma                           | Osteopontin   | ERK and p38         | Promoting macrophage infiltration                     | <i>In vivo and in vitro</i> | (Kale et al., 2014)         |
| esophageal squamous cell carcinoma | TDO2          | AKT/GSK3b/IL-8      | Promoting M2 polarization and recruitment             | <i>In vivo and in vitro</i> | (Zhao et al., 2021)         |
| Nasopharyngeal carcinoma           | MIF           | -                   | Inhibiting ferroptosis of macrophages                 | <i>In vivo and in vitro</i> | (Chen et al., 2021)         |
| Glioblastoma                       | MSI1          | -                   | Promoting M2 polarization                             | <i>In vivo and in vitro</i> | (Yang et al., 2021b)        |
| Lung cancer                        | succinic acid | PI3K/HIF-1 $\alpha$ | Promoting polarization of macrophages to TAMs         | <i>In vivo and in vitro</i> | (Wu et al., 2020b)          |
| Melanoma                           | SCOD          | -                   | Promoting M1 polarization of TAMs                     | <i>In vivo and in vitro</i> | (Sun et al., 2022)          |
| Glioblastoma multiforme            | FX            | ERK1/2 and AKT      | Promoting macrophages recruitment and M2 polarization | <i>In vivo and in vitro</i> | (Zhang et al., 2020)        |
| Pancreatic cancer                  | ANXA1         | -                   | Promoting M2 polarization                             | <i>In vivo and in vitro</i> | (Novizio et al., 2021)      |
| Breast cancer                      | Fra-1         | -                   | Promoting differentiation of macrophages into M2d     | <i>In vitro</i>             | (Wang et al., 2010)         |
| Lung cancer                        | IL1RL10       | Rab37/ST2           | Enhancing ratio of M1/M2                              | <i>In vitro</i>             | (Tzeng et al., 2018)        |
| Esophageal squamous cell carcinoma | PTEN          | PI3K/AKT            | Inducing M2 polarization                              | <i>In vitro</i>             | (Yang et al., 2021a)        |
| Melanoma                           | bcl-2         | -                   | Promoting M2 polarization                             | <i>In vivo and in vitro</i> | (Di Martile et al., 2020)   |
| esophageal squamous cell carcinoma | FOXO1         | FAK/PI3K/AKT        | Promoting M2 polarization                             | <i>In vivo and in vitro</i> | (Wang et al., 2020)         |
| PDA                                | DCLK1         | -                   | Promoting M2 polarization                             | <i>In vivo and in vitro</i> | (Chandrakesan et al., 2020) |
| Breast cancer                      | TFEB          | STAT3               | Promoting M2 polarization                             | <i>In vivo and in vitro</i> | (Fang et al., 2017)         |
| Ovarian cancer                     | glutamine     | -                   | Promoting M2 polarization                             | <i>In vitro</i>             | (Menga et al., 2021)        |

|                            |          |              |                                |   |                             |                              |
|----------------------------|----------|--------------|--------------------------------|---|-----------------------------|------------------------------|
|                            |          | synthetase   |                                |   |                             |                              |
| Breast cancer              |          | SNAIL1       | -                              | Regulating macrophage polarization                                      | <i>In vivo and in vitro</i> | (Brenot et al., 2018)        |
| esophageal carcinoma       | squamous | S100A7       | -                              | Promoting M2 polarization and recruitment of macrophages to tumor sites | <i>In vivo and in vitro</i> | (Lu et al., 2021)            |
| Breast cancer              |          | Kindlin-2    | -                              | Promoting recruitment of macrophages                                    | <i>In vivo and in vitro</i> | (Sossey-Alaoui et al., 2017) |
| Non-small cell lung cancer |          | Angptl2      | -                              | Inducing M2 polarization  | <i>In vivo and in vitro</i> | (Wei et al., 2017)           |
| Ovarian Cancer             |          | -            | PPA R $\gamma$ /NF- $\kappa$ B | Promoting M2 polarization   | <i>In vitro</i>             | (Deng et al., 2015)          |
| DLBCL                      |          | GP130        | STAT3                          | Promoting M2 polarization   | <i>In vitro</i>             | (Ling et al., 2022)          |
| Non-small cell lung cancer |          | LAMC2        | -                              | Promoting macrophage infiltration                                       | <i>In vitro</i>             | (Liu et al., 2021)           |
| Breast cancer              |          | Oncostatin M | mTORC2-Akt1                    | Promoting M2 polarization   | <i>In vivo and in vitro</i> | (Shrivastava et al., 2019)   |
| -                          |          | Nodal        | -                              | Promoting M2 polarization   | <i>In vitro</i>             | (Wang et al., 2014)          |

7

8

9

10

11

12

13

14

Table 3 Natural products targeting macrophages in TME

| Name                        | Cancer                        | Nature         | Target                       | Effect  | Model                              | Dose  | Refs                 |
|-----------------------------|-------------------------------|----------------|------------------------------|---|------------------------------------|---|----------------------|
| KSG-002                     | Breast cancer                 | Extract        | NF- $\kappa$ B/ TNF $\alpha$ | Inhibiting M2 polarization                                | <i>In vivo</i> and <i>in vitro</i> | 500 mg/kg/day in mice; 50, 100, 200, 500 $\mu$ g/mL in cells        | (Woo et al., 2013)   |
| <i>Taraxacum mongolicum</i> | Triple-negative breast cancer | Extract        | STAT3 and PD-L1              | Inhibiting M2 polarization                                | <i>In vitro</i>                    | 20, 40, 80 $\mu$ g/mL   | (Deng et al., 2021a) |
| EAT                         | Lung cancer                   | Extract        | -                            | Inhibiting M2 polarization                                | <i>In vitro</i>                    | 50, 100, 200 $\mu$ g/mL   | (Park, 2019)         |
| ARCR                        | Colorectal cancer             | Extract        | Sp1/ZFAS1/miR-153-3p/CCR5    | Inhibiting M2 polarization                                | <i>In vivo</i> and <i>in vitro</i> | 0.64 g/kg/day in cells; 6 g crude drug/kg/day in mice               | (Gu et al., 2022)    |
| Huaier extract              | Breast cancer                 | Extract        | -                            | Inhibiting M2 polarization and recruitment of macrophages | <i>In vivo</i> and <i>in vitro</i> | 4, 8 mg/mL in cells; 75 mg per mouse                                | (Li et al., 2016)    |
| Cordyceps sinensis          | Triple-negative breast cancer | Extract        | NF- $\kappa$ B               | Promoting M1 polarization                                 | <i>In vivo</i> and <i>in vitro</i> | 100, 200 mg/kg in mice; 0.1, 0.4 mg/mL in cells                     | (Li et al., 2020)    |
| MEMA                        | -                             | Extract        | STAT6 and STAT3              | Inhibiting M2 polarization and recruitment of macrophages | <i>In vitro</i>                    | 25, 50, 10 $\mu$ g/mL   | (Park et al., 2020b) |
| GLSP                        | Hepatocellular carcinoma      | Polysaccharide | -                            | Promoting M1 polarization                                 | <i>In vitro</i>                    | 200, 400, 800 $\mu$ g/mL  | (Song et al., 2021b) |
| Oligo-Fucoidan              | Colon cancer                  | Polysaccharide | -                            | Promoting M1 polarization                                 | <i>In vivo</i> and <i>in vitro</i> | 150 mg/kg in mice; 400 $\mu$ g/mL in cells                          | (Chen et al., 2020a) |
| Aiduqing                    | Breast cancer                 | Formula        | CXCL1                        | Promoting polarization of M2 into M1                      | <i>In vivo</i> and <i>in vitro</i> | 0.7, 1.4 g/kg/day in mice; 20, 40, 80, 100, 200 $\mu$ g/mL in cells | (Li et al., 2021)    |
| Yu-Ping-Feng                | Lewis lung cancer             | Decoction      | STAT1                        | Promoting M1 polarization                                 | <i>In vivo</i> and <i>in vitro</i> | 117 mg per mouse; 0.125, 0.25, 0.5, 1 mg/mL in cells                | (Wang et al., 2019)  |
| $\beta$ -carotene           | Colon cancer                  | Compound       | IL-6/STAT3                   | Inhibiting M2 polarization                                | <i>In vivo</i> and <i>in vitro</i> | 40 $\mu$ M in cells; 5, 15 mg/kg in mice                            | (Lee et al., 2020)   |
| Astragaloside IV            | Ovarian cancer                | Compound       | HMGB1/TLR4                   | Inhibiting M2 polarization                                | <i>In vitro</i>                    | 10 $\mu$ g/mL   | (Wang et al., 2021b) |
| Astragaloside               | Colorectal cancer             | Compound       | -                            | Promoting M1 polarization                                 | <i>In vivo</i> and <i>in vitro</i> | 15 mg/kg in mice; 10, 50, 100                                       | (Liu et al., 2020)   |


|                                    |                   |                 |                |   |      |                                    |   |                                  |
|------------------------------------|-------------------|-----------------|----------------|---|------|------------------------------------|---|----------------------------------|
| e IV                               |                   |                 |                |   |      | <i>vitro</i>                       | nM in cells   |                                  |
| Berberine                          | DLBCL             | Compound        | c-myc          | Promoting macrophage phagocytosis                         |      | <i>In vivo</i> and <i>in vitro</i> | 100 mg/kg in mice; 15, 30, 60 $\mu$ M in cells          | (Ren et al., 2021)               |
| Xanthoangelol                      | osteosarcoma      | Compound        | STAT           | Inhibiting M2 polarization                                |      | <i>In vivo</i> and <i>in vitro</i> | 25 and 50 mg/kg in mice; 5, 10, 25, 50 $\mu$ M in cells | (Sumiyoshi et al., 2015)         |
| 4-hydroxyderricin                  | osteosarcoma      | Compound        | -              | Inhibiting macrophage activation                          |      | <i>In vivo</i> and <i>in vitro</i> | 25, 50 mg/kg in mice; 5, 10, 25, 50 $\mu$ M in cells    | (Sumiyoshi et al., 2015)         |
| Resveratrol                        | Breast cancer     | Compound        | IL-6/STAT3     | Promoting M1 polarization                                 |      | <i>In vitro</i>                    | 40 mg/kg in mice; 5, 10, 25 $\mu$ M in cells            | (Cheuk et al., 2022)             |
| Resveratrol analog                 | Breast cancer     | Compound analog | -              | Promoting TAM differentiation into antitumor phenotype    | into | <i>In vivo</i> and <i>in vitro</i> | 1.5 mg/kg in mice; 1.25, 2.5, 5 $\mu$ M in cells        | (Jeong et al., 2014)             |
| Polyporus polysaccharide           | Bladder cancer    | Polysaccharide  | -              | Inhibiting M2 polarization                                |      | <i>In vitro</i>                    | 1, 10, 100 $\mu$ g/mL                                   | (Jia et al., 2021a)              |
| Cucurbitacin B                     | Colorectal cancer | Compound        | JAK-2/STAT3    | Inhibiting M2 polarization                                |      | <i>In vivo</i> and <i>in vitro</i> | 0.5, 1 mg/kg in mice; 0.4, 0.8 $\mu$ M in cells         | (Zhang et al., 2022)             |
| Curcumin                           | Lung cancer       | Compound        | p53            | Promoting M1 polarization                                 |      | <i>In vivo</i> and <i>in vitro</i> | 5, 10, 20 $\mu$ M                                       | (Xu et al., 2022a)               |
| Dihydroartemisinin                 | HNSCC             | Compound        | STAT3          | Inhibiting M2 polarization                                |      | <i>In vitro</i>                    | 50 $\mu$ M  | (Chen et al., 2020b)             |
| Dihydroartemisinin                 | Lewis carcinoma   | Lung Compound   | AKT/mTOR       | Promoting M1 polarization                                 |      | <i>In vivo</i> and <i>in vitro</i> | 12.5 mg/kg in mice; 0.5 ,1,5 ,10 $\mu$ M in cells       | (Xiao et al., 2022)              |
| Luteolin                           | Lewis carcinoma   | lung Compound   | -              | Inhibiting secretion in TAMs                              |      | <i>In vitro</i>                    | 1, 5, 10 $\mu$ M  | (Choi et al., 2016)              |
| Epigallocatechin gallate \         | Breast cancer     | Compound        | miR-16         | Inhibiting macrophage infiltration and M2 polarization    | and  | <i>In vivo</i> and <i>in vitro</i> | 10 mg/kg in mice; 100 $\mu$ M in cells                  | (Jang et al., 2013)              |
| Lupeol                             | Lewis carcinoma   | lung Compound   | -              | Inhibiting M2 polarization and recruitment of macrophages | and  | <i>In vitro</i>                    | 10, 20, 50, 100 $\mu$ M                                 | (Park et al., 2020a)             |
| 2-methylpyridine-1-ium-1-sulfonate | Colorectal cancer | Compound        | -              | Promoting M1 polarization                                 |      | <i>In vitro</i>                    | 2, 4, 6 $\mu$ M   | (Rastegari-Pouyani et al., 2022) |
| Triptolide                         | Ovarian cancer    | Compound        | PI3K/Akt/NF-kB | Inhibiting M2 polarization                                |      | <i>In vivo</i> and <i>in vitro</i> | 0.15 mg/kg/d in mice; 6.25,                             | (Le et al., 2021)                |

|                |                |          |       |   |  |   |                         |
|----------------|----------------|----------|-------|---|--|---|-------------------------|
| Corosolic acid | -              | Compound | STAT3 | Inhibiting M2 polarization  | <i>vitro</i><br><i>In vivo</i> and <i>in vitro</i> | 12.5, 25, 50, 100 nM in cells<br>17.5 mg/kg in mice; 10, 20, 30 µM in cells | (Fujiwara et al., 2014) |
| Oleanolic acid | -              | Compound | STAT3 | Inhibiting M2 polarization  | <i>In vitro</i>                                    | 10, 20, 30 µM in cells  | (Fujiwara et al., 2014) |
| Ovatodiolide   | Bladder cancer | Compound | -     | Reducing expression of tumor promoting factors in TAM exosomes and inhibiting M2 polarization | <i>In vivo</i> and <i>in vitro</i>                 | 5 mg/kg in mice   | (Wu et al., 2020a)      |

---


16

17





Cancer cell



Exosome



Macrophage

PTEN

AKT

STAT6

FBXW7


NOTCH

PPAR $\gamma$

NF- $\kappa$ B


STAT3


M2 polarization



Cancer cell

Macrophage





Cancer cell



Fibroblast



NK cell



Chemokines



Macrophage



Cancer stem cell



T cell



Endothelial cell




Exosome




Myeloid-derived suppressor cell


## Cancer cell





Regulated by proteins in macrophages



Affected by cancer cells



Affected by the surrounding environment




Macrophage


Polarization



**Natural products**



M2



Tumor development